GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Puma Biotechnology Inc (NAS:PBYI) » Definitions » E10

Puma Biotechnology (Puma Biotechnology) E10 : $-4.35 (As of Mar. 2024)


View and export this data going back to 2012. Start your Free Trial

What is Puma Biotechnology E10?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

Puma Biotechnology's adjusted earnings per share data for the three months ended in Mar. 2024 was $-0.100. Add all the adjusted EPS for the past 10 years together and divide 10 will get our e10, which is $-4.35 for the trailing ten years ended in Mar. 2024.

During the past 3 years, the average E10 Growth Rate was -0.20% per year. During the past 5 years, the average E10 Growth Rate was 0.30% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the E10 growth rate using E10 data.

During the past 13 years, the highest 3-Year average E10 Growth Rate of Puma Biotechnology was 2.30% per year. The lowest was -0.80% per year. And the median was -0.25% per year.

As of today (2024-05-14), Puma Biotechnology's current stock price is $5.135. Puma Biotechnology's E10 for the quarter that ended in Mar. 2024 was $-4.35. Puma Biotechnology's Shiller PE Ratio of today is .


Puma Biotechnology E10 Historical Data

The historical data trend for Puma Biotechnology's E10 can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Puma Biotechnology E10 Chart

Puma Biotechnology Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
E10
Get a 7-Day Free Trial Premium Member Only Premium Member Only -4.53 -4.40 -4.71 -4.57 -4.43

Puma Biotechnology Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
E10 Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -4.59 -4.58 -4.54 -4.43 -4.35

Competitive Comparison of Puma Biotechnology's E10

For the Biotechnology subindustry, Puma Biotechnology's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Puma Biotechnology's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Puma Biotechnology's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Puma Biotechnology's Shiller PE Ratio falls into.



Puma Biotechnology E10 Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. When we calculate the today's Shiller P/E ratio of a stock, we use today's price divided by E10.

What is E10? How do we calculate E10?

E10 is the average of the inflation adjusted earnings of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the E10 of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the earnings from 2001 through 2010.

We adjusted the earnings of 2001 earnings data with the total inflation from 2001 through 2010 to the equivalent earnings in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart earned $1 a share in 2001, then the 2001's equivalent earnings in 2010 is $1.4 a share. If Wal-Mart earns $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 earnings in 2010 is $1.35. So on and so forth, you get the equivalent earnings of past 10 years. Then you add them together and divided the sum by 10 to get E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Puma Biotechnology's adjusted earnings per share data for the three months ended in Mar. 2024 was:

Adj_EPS= Earnings per Share (Diluted) /CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=-0.1/129.4194*129.4194
=-0.100

Current CPI (Mar. 2024) = 129.4194.

Puma Biotechnology Quarterly Data

per share eps CPI Adj_EPS
201406 -1.290 100.560 -1.660
201409 -1.190 100.428 -1.534
201412 -1.570 99.070 -2.051
201503 -1.660 99.621 -2.157
201506 -2.010 100.684 -2.584
201509 -1.870 100.392 -2.411
201512 -1.900 99.792 -2.464
201603 -2.190 100.470 -2.821
201606 -2.050 101.688 -2.609
201609 -2.020 101.861 -2.567
201612 -2.040 101.863 -2.592
201703 -1.970 102.862 -2.479
201706 -2.100 103.349 -2.630
201709 -2.070 104.136 -2.573
201712 -1.710 104.011 -2.128
201803 -0.650 105.290 -0.799
201806 -1.170 106.317 -1.424
201809 -0.370 106.507 -0.450
201812 -0.800 105.998 -0.977
201903 -0.260 107.251 -0.314
201906 -0.970 108.070 -1.162
201909 -0.440 108.329 -0.526
201912 -0.290 108.420 -0.346
202003 -0.430 108.902 -0.511
202006 0.080 108.767 0.095
202009 -0.790 109.815 -0.931
202012 -0.380 109.897 -0.448
202103 0.400 111.754 0.463
202106 -0.130 114.631 -0.147
202109 -1.090 115.734 -1.219
202112 0.100 117.630 0.110
202203 -0.080 121.301 -0.085
202206 0.210 125.017 0.217
202209 -0.010 125.227 -0.010
202212 -0.120 125.222 -0.124
202303 0.030 127.348 0.030
202306 0.050 128.729 0.050
202309 0.120 129.860 0.120
202312 0.250 129.419 0.250
202403 -0.100 129.419 -0.100

Add all the adjusted EPS together and divide 10 will get our e10.


Puma Biotechnology  (NAS:PBYI) E10 Explanation

If a company grows much fast than inflation, E10 may underestimate the company's earnings power. Shiller PE Ratio can seem to be too high even the actual P/E is low.

For the Shiller P/E, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller P/E is also called PE10.

The Shiller P/E was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.


Be Aware

Shiller PE Ratio works better for cyclical companies. It gives you a better idea on the company's real earnings power.


Puma Biotechnology E10 Related Terms

Thank you for viewing the detailed overview of Puma Biotechnology's E10 provided by GuruFocus.com. Please click on the following links to see related term pages.


Puma Biotechnology (Puma Biotechnology) Business Description

Traded in Other Exchanges
N/A
Address
10880 Wilshire Boulevard, Suite 2150, Los Angeles, CA, USA, 90024
Puma Biotechnology Inc is a biopharmaceutical company with a focus on the development and commercialization of innovative products to enhance cancer care. The company in-licenses the global development and commercialization rights to PB272 (neratinib, oral), PB272 (neratinib, intravenous) and PB357. Neratinib, oral was approved by the U.S. FDA in 2017 for the extended adjuvant treatment of adult patients with early stage HER2-overexpressed/amplified breast cancer, following adjuvant trastuzumab-based therapy, and is marketed in the US as NERLYNX.
Executives
Alan H Auerbach director, 10 percent owner, officer: PRESIDENT, CEO & SECRETARY 10940 WILSHIRE BLVD. SUITE 600, LOS ANGELES CA 90024
Alvin F Wong officer: Chief Scientific Officer C/O PUMA BIOTECHNOLOGY, INC., 10880 WILSHIRE BOULEVARD, SUITE 2150, LOS ANGELES CA 90024
Maximo F Nougues officer: Chief Financial Officer C/O PUMA BIOTECHNOLOGY, INC., 10880 WILSHIRE BOULEVARD, SUITE 2150, LOS ANGELES CA 90024
Jeffrey Jerome Ludwig officer: Chief Commercial Officer C/O PUMA BIOTECHNOLOGY, INC., 10880 WILSHIRE BOULEVARD, SUITE 2150, LOS ANGELES CA 90024
Douglas M Hunt officer: See Remarks C/O PUMA BIOTECHNOLOGY,INC., 10880 WILSHIRE BOULEVARD, SUITE 2150, LOS ANGELES CA 90024
Michael Patrick Miller director C/O JAZZ PHARMACEUTICALS PLC, 5TH FL, WATERLOO EXCHANGE, WATERLOO RD, DUBLIN 4 L2
Adrian Senderowicz director C/O PUMA BIOTECHNOLOGY, INC., 10880 WILSHIRE BOULEVARD, SUITE 2150, LOS ANGELES CA 90024
Troy Edward Wilson director C/O KURA ONCOLOGY, INC., 12730 HIGH BLUFF DRIVE, SUITE 400, SAN DIEGO CA 92130
Allison Dorval director C/O INSULET CORPORATION, 600 TECHNOLOGY PARK DRIVE, SUITE 200, BILLERICA MA 01821
Brian M Stuglik director C/O VERASTEM, INC., 117, NEEDHAM MA 02494
Jay M Moyes director
Alessandra Cesano director 700 BALTIC CIRCLE, SUITE 716, REDWOOD CITY CA 94065
Ann Calby Miller director C/O INOVIO PHARMACEUTICALS, INC., 660 W. GERMANTOWN PIKE, SUITE 110, PLYMOUTH MEETING PA 19462
Richard Paul Bryce officer: SR VP, CLINICAL RESEARCH & DEV C/O PUMA BIOTECHNOLOGY, INC., 10880 WILSHIRE BOULEVARD, SUITE 2150, LOS ANGELES CA 90024
Hugh O'dowd director C/O NEON THERAPEUTICS, INC., 40 ERRIE STREET SUITE 110, CAMBRIDGE MA 02139

Puma Biotechnology (Puma Biotechnology) Headlines

From GuruFocus